Beam Therapeutics, Inc. (BEAM)
NASDAQ:BEAM
Want to see BEAM full AI Analyst Report?
BEAM Stock Chart & Stats
$31.39
-$0.69(-2.55%)
At close: 4:00 PM EST
$31.39
-$0.69(-2.55%)
Day’s Range― - ―
52-Week Range$15.60 - $36.44
Previous CloseN/A
Volume491.48K
Average Volume (3M)2.17M
Market Cap
$3.02B
Enterprise Value$3.35B
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$250.82M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Aug 11, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding102,879,210
10 Day Avg. Volume2,039,814
30 Day Avg. Volume2,170,653
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue20.43
Enterprise Value/Gross Profit-63.00
Enterprise Value/Ebitda-53.36
Forecast
1Y Price Target
$51.58Price Target Upside64.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-4.42
Revenue Forecast (FY)$70.79M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthTTM revenue up ~17% signals durable progress in program advancement and commercial partnerships rather than a one-quarter blip. Consistent top-line expansion supports continued R&D investment, attracts collaborators, and provides evidence of underlying demand or milestone-driven cash inflows over months.
Relatively Strong Balance Sheet And Low LeverageLow debt-to-equity (~0.13) and meaningful equity and asset bases give the company lasting financial flexibility to fund trials and partnerships. This reduces near-term refinancing pressure, lowers dilution risk versus highly leveraged peers, and supports multiyear clinical programs.
Partnership-driven Revenue ModelA collaboration/licensing model provides recurring, milestone-linked funding that is non-dilutive relative to equity raises. Strategic partnerships can de-risk development, accelerate programs via partner resources, and create durable revenue streams tied to clinical or regulatory progress.
Bears Say
High Cash Burn And Negative Cash FlowSustained ~-$370M OCF and ~-$384M FCF indicate heavy runway consumption and ongoing reliance on external financing or partner payments. Over a multi-month horizon, this constrains strategic optionality, risks dilution if equity raises are needed, and forces program prioritization.
Deep And Persistent Operating LossesA ~-49% net margin reflects structural unprofitability that is likely to persist while clinical development continues. Prolonged losses can erode equity returns, increase dependence on partner funding, and make long-term self-sustaining operations contingent on achieving costly regulatory or commercial milestones.
Gross Profit Volatility And Revenue Quality UncertaintySwitching from strong gross profit to negative in the TTM period indicates revenue and cost timing mismatches or one-off items. This volatility undermines margin predictability, complicates budgeting and partner negotiations, and raises the risk that revenue gains may not convert to stable long-term margins.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics, Inc.’s price range in the past 12 months?
Beam Therapeutics, Inc. lowest stock price was $15.60 and its highest was $36.44 in the past 12 months.
What is Beam Therapeutics, Inc.’s market cap?
Beam Therapeutics, Inc.’s market cap is $3.02B.
When is Beam Therapeutics, Inc.’s upcoming earnings report date?
Beam Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 64 days.
How were Beam Therapeutics, Inc.’s earnings last quarter?
Beam Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$1.028 by $0.118.
Is Beam Therapeutics, Inc. overvalued?
According to Wall Street analysts Beam Therapeutics, Inc.’s price is currently Undervalued.
Does Beam Therapeutics, Inc. pay dividends?
Beam Therapeutics, Inc. pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics, Inc. dividends here
What is Beam Therapeutics, Inc.’s EPS estimate?
Beam Therapeutics, Inc.’s EPS estimate is -1.11.
How many shares outstanding does Beam Therapeutics, Inc. have?
Beam Therapeutics, Inc. has 102,879,210 shares outstanding.
What happened to Beam Therapeutics, Inc.’s price movement after its last earnings report?
Beam Therapeutics, Inc. reported an EPS of -$0.91 in its last earnings report, beating expectations of -$1.028. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Beam Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.58 (64.33% Upside)
$51.58 (64.33% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.94%
12-Months-Change
Fundamentals
Return on Equity
-5.89%
Trailing 12-Months
Asset Growth
0.95%
Trailing 12-Months
Company Description
Beam Therapeutics, Inc.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial positive momentum: a new liver-targeted PKU program with strong preclinical efficacy, constructive FDA engagement around an umbrella platform approach, demonstrated LNP and manufacturing capabilities, and a major non-dilutive financing that extends runway into mid-2029. Key risks highlighted include regulatory ambiguity for novel individualized pathways, the large diversity of PAH variants (necessitating personalized approaches), limited public detail on bystander/off-target profiles, and conditional milestone-based financing. On balance, the updates emphasize progress, resources, and clear near-term milestones while acknowledging technical and regulatory uncertainties that are typical for platform-based gene editing development.View all BEAM earnings summariesBEAM Stock 12 Month Forecast
Average Price Target
$51.58
▲(64.33% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
3.63% Insiders
21.57% Mutual Funds
46.72% Other Institutional Investors
0.09% Public Companies and Individual Investors